News & Views |
Featured
-
-
News & Views |
Sunitinib versus interferon-α in metastatic RCC
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
- Jason E. Faris
- & M. Dror Michaelson
-
Case Study |
Interaction between capecitabine and brivudin in a patient with breast cancer
This Case Study describes a patient with breast cancer who was treated with capecitabine and experienced a severe adverse event when treated with brivudin for a herpes infection. The authors discuss drug–drug interactions and management of the associated toxic effects.
- José M. Baena-Cañada
- , María J. Martínez
- & Pedro Muriel-Cueto
-
Opinion |
Explanations for worsening cancer survival
When cancer survival statistics worsen over time a common assumption is that care must have deteriorated. A variety of reasons cause cancer survival to drop, including improved diagnosis of premalignant lesions, deleterious changes in the distribution of prognostic factors, and changes in the distribution of sociodemographic characteristics. In this article, the pitfalls of comparing published population-based survival data from different time periods or populations are discussed.
- Esther de Vries
- , Henrike E. Karim-Kos
- & Jan Willem W. Coebergh